Table 4.
Pathways significantly represented in the single lines
| Treatment type | p-val | Pathway affected |
| HT-29 | ||
| E | 0,0127 | Parkinson's disease |
| 0,0216 | Bisphenol A degradation | |
| 0,027 | Nucleotide sugars metabolism | |
| 0,028 | ECM-receptor interaction | |
| 0,029 | Ubiquitin mediated proteolysis | |
| 0,03 | Neurodegenerative disorders | |
| 0,03 | Prion disease | |
| 0,03 | mTOR signaling pathway | |
| Cx10 | 0,0001 | Ribosome |
| 0,0288 | Calcium signaling pathway | |
| 0,0467 | Prion disease | |
| Gb | 0,0056 | T cell receptor signaling pathway |
| 0,0115 | mTOR signaling pathway | |
| 0,0163 | Natural killer cell mediated cytotoxicity | |
| 0,0187 | Pentose and glucuronate interconversions | |
| 0,0202 | Tight junction | |
| 0,0214 | Starch and sucrose metabolism | |
| 0,0242 | Insulin signaling pathway | |
| 0,0293 | Long-term potentiation | |
| 0,0332 | GnRH signaling pathway | |
| 0,0352 | TGF-beta signaling pathway | |
| 0,0402 | MAPK signaling pathway | |
| 0,0482 | D-Glutamine and D-glutamate metabolism | |
| 0,0497 | Cell Communication | |
| Cx10 + E | 0,0001 | Oxidative phosphorylation |
| 0,0211 | Benzoate degradation via hydroxylation | |
| 0,0254 | Chronic myeloid leukemia | |
| 0,0277 | Antigen processing and presentation | |
| 0,0319 | Ribosome | |
| 0,0461 | Notch signaling pathway | |
| Gb + E | 0,0002 | Cholera – Infection |
| 0,0003 | PPAR signaling pathway | |
| 0,0075 | Tyrosine metabolism | |
| 0,0090 | Fluorene degradation | |
| 0,0126 | Benzoate degradation via hydroxylation | |
| 0,0197 | Insulin signaling pathway | |
| 0,0205 | Fatty acid metabolism | |
| 0,0208 | Calcium signaling pathway | |
| 0,0225 | Neuroactive ligand-receptor interaction | |
| 0,0338 | Oxidative phosphorylation | |
| 0,0351 | Glycerolipid metabolism | |
| 0,0385 | Glioma | |
| 0,0428 | Urea cycle and metabolism of amino groups | |
| 0,0442 | Neurodegenerative disorders | |
| 0,0442 | Styrene degradation | |
| 0,0442 | Fatty acid biosynthesis | |
| 0,0445 | 1- and 2-Methylnaphthalene degradation | |
| Caco-2 | ||
| E | 0,0022 | Epithelial cell signaling in Helicobacter pylori infection |
| 0,0034 | Tight junction | |
| 0,0133 | Adherent junction | |
| 0,0152 | Dentatorubropallidoluysian atrophy (DRPLA) | |
| 0,0179 | Apoptosis | |
| 0,0422 | Methionine metabolism | |
| 0,0436 | D-Glutamine and D-glutamate metabolism | |
| 0,0445 | Selenoamino acid metabolism | |
| 0,0481 | Glycan structures – biosynthesis 2 | |
| 0,0496 | Toll-like receptor signaling pathway | |
| Cx10 | 0,0008 | Oxidative phosphorylation |
| 0,0134 | Ribosome | |
| 0,0179 | Cell cycle | |
| 0,0193 | Metabolism of xenobiotics by cytochrome P450 | |
| 0,0356 | Glycan structures – biosynthesis 1 | |
| 0,0489 | O-Glycan biosynthesis | |
| Gb | 0,0001 | Ribosome |
| 0,0106 | Basal cell carcinoma | |
| 0,0135 | Cell Communication | |
| 0,0308 | Valine, leukine and isoleukine degradation | |
| 0,0394 | Fatty acid metabolism | |
| Cx10 + E | 0.0141 | Gap junction |
| 0.0163 | GnRH signaling pathway | |
| 0.0169 | ECM-receptor interaction | |
| 0.0364 | Vitamin B6 metabolism | |
| Gb + E | 0,0183 | C5-Branched dibasic acid metabolism |
| 0,0369 | Tight junction |
E = Epidermal growth factor 10 nmol/L; Cx10 = cetuximab 10 nmol/L; Gb = gefitinib. 1 μmol/L;
Cx10 + E = cetuximab 10 nmol/L + Epidermal growth factor 10 nmol/L; Gb + E = gefitinib 1 μmol/L + Epidermal growth factor 10 nmol/L. The pathways were considered significant if P ≤ 0.05.